Biomarker Insights from KRAS P.G12C-Mutated Subjects Treated with Sotorasib in Codebreak 100
Time: 9:30 am
day: Day One
Details:
- Baseline biomarker subgroup associations with response in NSCLC subjects
- 2-year follow-up assessing biomarker correlates for NSCLC subjects deriving long-term benefit from sotorasib treatment
- Analysis of acquired mutations NSCLC and CRC to treatment to inform rational combo therapy
